Sorin Group's newest generation C5 HLM system receives FDA clearance

Sorin Group, (MIL:SRN) (Reuters Code: SORN.MI), a global company and a leader in the treatment of cardiovascular diseases, announced today the U.S. Food and Drug Administration (FDA) clearance of its newest generation C5 Heart-Lung Machine (HLM).

“The C5 HLM provides another example of Sorin Group’s commitment to developing solutions that meet the needs of both patients and clinicians. Our focus on delivering product and service excellence helps maintain our worldwide leading position”

A Heart-Lung Machine is a sophisticated piece of medical equipment that provides blood oxygenation and circulation to organs and the brain while the patient's heart and lungs are temporarily stopped during a cardio-thoracic surgical procedure.

Sorin’s C5 HLM is the culmination of over 25 years of experience in extracorporeal perfusion system design and manufacturing.

The C5 HLM builds on the state-of-the-art technology and proven interface of Sorin’s S5 industry-standard HLM, while being lighter in weight and more compact. The C5 has excellent manoeuvrability and a well thought-out, logical structure, functional ergonomic design and reliable safety systems. Its solid, brushed stainless steel housing reflects the product´s high quality.

With the C5 HLM, Sorin obtained FDA clearance within one month of submission, the shortest clearance time for a heart lung machine on company record. The introduction of the C5 to the US market will further strengthen Sorin Group’s world leading position in the cardiopulmonary bypass market.

“The C5 HLM provides another example of Sorin Group’s commitment to developing solutions that meet the needs of both patients and clinicians. Our focus on delivering product and service excellence helps maintain our worldwide leading position”, said Michel Darnaud, President, Cardiopulmonary Business Unit and Intercontinental, Sorin Group.

The C5 HLM will be showcased for the first time in the USA at CREF – Cardiothoracic Surgery Symposium – in Newport Beach, CA on March 4-7, 2010.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
From Dr. Oz to heart valves: A tiny device charted a contentious path through the FDA